Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

Table 6 Cumulative chronic sensory neuropathy rates in selected phase III trials involving oxaliplatin and 5-FU based combination chemotherapy

Ref.	Regimen	Oxaliplatin Dose: mg/m²	Planned Oxaliplatin Dose intensity: mg/m²/wk	Treatment	≥ grade 3
25	OX + FU/LV^a chronotherapy	Both arms: 20 days 1–5 q 3 wk 20/10.5 hr CI; peak at 4:00 pm	33.3	First line	16%
	Constant rate	20/24 hr CI			31%
26	OX + FU/LV^b	125/6 hr day 1 q 3 wk 10:00 am to 4:00 pm	41.7	First line	10%
3	FOLFOX 4	85/2 hr day 1 q 2 wk	42.5	First line	18.2%
4	FOLFOX 4	85/2 hr day 1 q 2 wk	42.5	First line	18%
	IROX	85/1.5 hr day 1 q 3 wk	28.3		7%
5	FOLFOX 6	100/2 hr day 1 q 2 wk	50	First line	34%
27	FUFOX	50/2 hr days 1, 8, 15, 22 q 5 wk^c	40	First line	17%
28	FUFOX	50/x hr days 1, 8, 15, 22 q 5 wk^c	40	First line	25%
	CAPOX	70/x hr d 1, 8 q 3 wk	46.7		16%
17	FOLFOX 4	85/2 hr day 1 q 2 wk	42.5	Adjuvant	12%
5	FOLFOX 6	100/2 hr day 1 q 2 wk	50	Second line^d	20%
29	FOLFOX 4	85/2 hr day 1 q 2 wk	42.5	Second or third line^e	3%^f

FOLFOX: oxaliplatin and biweekly FULV2; IROX: oxaliplatin and irinotecan;
FUFOX: oxaliplatin and weekly 24 hour infusional 5-FU/LV; CAPOX: capecitabine and oxaliplatin
^a 5-FU 600 mg/m² and LV 300 mg/m² daily for 5 days over 12 hr with peak at either 04:00 am or over 24 hr by constant rate infusion; ^b 5-FU 700 mg/m² and LV 300 mg/m² daily for 5 days over 12 hr with peak at 04:00 am; ^c after the first four cycles, oxaliplatin given every 2 weeks; ^d patients had previously progressed on FOLFIRI; ^e Grade 3–4 acute, cold-sensitive paresthesia also occurred in 3% of patients.

ISSN: 1471-2407